Vatalanib in Treating Patients With Recurrent or Progressive Meningioma
Status:
Completed
Trial end date:
2013-07-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Vatalanib may stop the growth of tumor cells by blocking blood flow to the tumor
and by blocking some of the enzymes needed for cell growth.
PURPOSE: This phase II trial is studying how well vatalanib works in treating patients with
recurrent or progressive meningioma.